Zydus Wellness net sales up by 113.7% in Q3 FY26
Glucon-D maintained its leadership position with a 59% MAT market share
Glucon-D maintained its leadership position with a 59% MAT market share
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The new functionality complements Parse’s existing Evercode immune products
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Subscribe To Our Newsletter & Stay Updated